OPEN APP
Home / Science / Health /  Merck’s Covid pill results raise hopes for developing world
Listen to this article

As Merck & Co. races ahead with an experimental pill that could play a pivotal role in the fight against Covid-19, efforts are intensifying to bring the drug to developing countries that have struggled to vaccinate their populations.

The global health agency Unitaid and its partners hope to reach an agreement as soon as next week to secure the first supplies of the antiviral treatment for lower- and middle-income nations, Philippe Duneton, its executive director, said in an interview. Unitaid has been in discussions with the company and generic manufacturers, he said.

“This is really what we’ve waited for all these months," he said. “There is a window of hope with this treatment, and now we need to collectively make it work for people" in less well-to-do countries.

On the vaccine front, lower-income nations have been left behind. About nine months after the arrival of Covid shots, more than 55 countries have yet to vaccinate 10% of their populations. More than two dozen nations are below 2%.

If the medication hits the market, it could be a turning point in the pandemic. Results Friday were so positive that Merck and partner Ridgeback Biotherapeutics LP -- in consultation with independent trial monitors and the U.S. Food and Drug Administration -- elected to stop enrolling patients and begin the process of gaining regulatory clearance. 

Merck plans to submit the data to other regulators worldwide. 

Licensing Deals

The company earlier this year announced that it had signed non-exclusive voluntary licensing agreements for the drug with five generic manufacturers in India in a bid to accelerate availability in more than 100 low- and middle-income countries following approvals or emergency authorization by local regulatory agencies.

Potentially the drug could be very cheap to manufacture and available at a low cost in developing nations, benefiting millions of people, Andrew Hill, a senior research fellow at the University of Liverpool, wrote in an email. 

“This could be a major advance in the treatment of Covid-19," he said.

The company said in a statement that it expects to produce 10 million courses of treatment by year-end, with more expected in 2022. In June, the company agreed to a $1.2 billion supply deal with the U.S. government, under which it would provide 1.7 million courses of the treatment.

More stories like this are available on bloomberg.com

©2021 Bloomberg L.P.

This story has been published from a wire agency feed without modifications to the text.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Never miss a story! Stay connected and informed with Mint. Download our App Now!!

Close
×
Edit Profile
My ReadsRedeem a Gift CardLogout